Victoria Johnson

Regeneron's innovative antibody therapies show promising results in alleviating cat and birch allergies.

Intralesional triamcinolone showed significantly greater hair regrowth and patient satisfaction.

An audio recap of the top 5 stories in healthcare news from the week of 08/31-9/5.

A study links paternal prepubertal passive smoke exposure to impaired lung function in offspring.

August 2025 saw a number of novel approvals and expert perspectives for World Lung Cancer Day.

Agios announces a 3-month extension for mitapivat's FDA review.

The TETON-2 study met its primary endpoint, significantly improveing lung function in IPF.

An audio recap of the top 5 stories in healthcare news from the week of 08/24-08/30.

Finerenone reduced diuretic needs while improving outcomes across various diuretic therapies.

The new guidelines, updated from 2015, are informed by 194 systematic reviews, and 133 RCTs.

The therapy's, marketed as Papzimeos, approval is supported by data from a pivotal Phase 1/2 clinical trial.

Discover how precision medicine and advanced biologics are revolutionizing COPD and asthma management, enhancing patient outcomes and quality of life.

The therapy was approved based off of positive data from the pivotal ASPEN trial.

One year after neffy's approval, 4 clinicians and 1 PharmD examine its continuing impact on the field.

July 2025 saw a number of updates in COPD management and new research on RSV and COVID.

Discover the evolving landscape of hypertriglyceridemia treatment, focusing on innovative therapies and improved diagnostic strategies for FCS and MCS.

Insights from Lungcast Interviews with Experts Leading the Charge in Detection and Therapy

The therapy was originally approved under the name Alhemo for people with hemophilia ages 12 and up without inhibitors.

The new requirements follow a May Advisory Committee meeting that went over the latest long-term data on opioid risks.

Experts discuss the evolving management of asthma and COPD.

Patients and clinicians perceived a gap that largely didn't exist in views on diet's role in IBD.

A multidisciplinary care program achieved a 95% cure rate with Sofosbuvir/Velpatasvir therapy.

RSV hospitalizations in older adults lead to worse health outcomes and increased cardiovascular risks, highlighting the need for vaccination and monitoring.

Post-COVID CT guidance favors low-dose imaging, clear terms, and precise timing.

Genentech reveals mixed results for astegolimab in COPD trials, highlighting challenges in treatment options for this serious respiratory disease.

Endeavor BioMedicines' Taladegib gains orphan drug status for idiopathic pulmonary fibrosis, showing promise in improving lung function and patient outcomes.

Discover how recent advancements in biologic therapies transform severe asthma treatment, emphasizing personalized care and the importance of biomarker-driven decisions.

New research highlights significant declines in cardiovascular screenings for U.S. adults with disabilities during the COVID-19 pandemic, revealing ongoing healthcare disparities.

New data from a UMichigan survey found that 8% of preventative aspirin users had not even discussed their use with any health care provider.